Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2
Autor: | Yaqiong Zheng, Zhou Xiong, Shi Tang, Wanlei Wu, Lei Liu, Wanbing Liu, Wenxu Ni, Guomei Kou, Li Tan, Shangen Zheng, Qiongshu Wang, Yinjuan Ding |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Microbiology (medical) COVID-19 diagnosis IgM Coronavirus disease 2019 (COVID-19) IgG Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pneumonia Viral 030106 microbiology Enzyme-Linked Immunosorbent Assay spike protein medicine.disease_cause law.invention Betacoronavirus 03 medical and health sciences COVID-19 Testing law antibody medicine Humans Immunoassays Pandemics Coronavirus chemistry.chemical_classification biology Clinical Laboratory Techniques SARS-CoV-2 business.industry COVID-19 Spike Protein Virology 030104 developmental biology Enzyme Immunoglobulin M chemistry Immunoglobulin G Spike Glycoprotein Coronavirus Recombinant DNA biology.protein ELISA Antibody Coronavirus Infections business nucleocapsid protein Nucleic acid detection |
Zdroj: | Journal of Clinical Microbiology |
ISSN: | 1098-660X 0095-1137 |
DOI: | 10.1128/jcm.00461-20 |
Popis: | At present, PCR-based nucleic acid detection cannot meet the demands for coronavirus infectious disease (COVID-19) diagnosis. Two hundred fourteen confirmed COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command of the People’s Liberation Army between 18 January and 26 February 2020 were recruited. Two enzyme-linked immunosorbent assay (ELISA) kits based on recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein (rN) and spike protein (rS) were used for detecting IgM and IgG antibodies, and their diagnostic feasibility was evaluated. At present, PCR-based nucleic acid detection cannot meet the demands for coronavirus infectious disease (COVID-19) diagnosis. Two hundred fourteen confirmed COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command of the People’s Liberation Army between 18 January and 26 February 2020 were recruited. Two enzyme-linked immunosorbent assay (ELISA) kits based on recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein (rN) and spike protein (rS) were used for detecting IgM and IgG antibodies, and their diagnostic feasibility was evaluated. Among the 214 patients, 146 (68.2%) and 150 (70.1%) were successfully diagnosed with the rN-based IgM and IgG ELISAs, respectively; 165 (77.1%) and 159 (74.3%) were successfully diagnosed with the rS-based IgM and IgG ELISAs, respectively. The positive rates of the rN-based and rS-based ELISAs for antibody (IgM and/or IgG) detection were 80.4% and 82.2%, respectively. The sensitivity of the rS-based ELISA for IgM detection was significantly higher than that of the rN-based ELISA. We observed an increase in the positive rate for IgM and IgG with an increasing number of days post-disease onset (d.p.o.), but the positive rate of IgM dropped after 35 d.p.o. The positive rate of rN-based and rS-based IgM and IgG ELISAs was less than 60% during the early stage of the illness, 0 to 10 d.p.o., and that of IgM and IgG was obviously increased after 10 d.p.o. ELISA has a high sensitivity, especially for the detection of serum samples from patients after 10 d.p.o., so it could be an important supplementary method for COVID-19 diagnosis. |
Databáze: | OpenAIRE |
Externí odkaz: |